Utility Menu French

National Association of Pharmacy Regulatory Authorities

Provinces French

Main navigation French


Recherchez dans la base de données des Annexes nationales de médicaments

Commencez votre recherche en utilisant le nom générique du produit :

Recherche par annexe
Réinitialiser

ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.

Nom du médicament (en anglais) Commentaire Annexe Date
IbafloxacinPDL I DEC / 13
Ibandronic acid or its saltsPDL I DEC / 13
Ibogaine or its salts or derivatives or analoguesPDL I MAY / 17
Ibrutinib or its saltsPDL I DEC / 14
Ibuprofen or its saltsPDL

For veterinary use.

I DEC / 13
Ibuprofen or its saltsPDL

For human use - except when sold in an oral dosage form that provides 400 mg or less per dosage unit or in a modified-release oral dosage form that provides 600 mg or less per dosage unit.

I AUG / 16
Ibuprofen or its salts. when sold in an immediate release dosage form containing 400 mg or less per oral dosage unit (in package sizes exceeding 18,000 mg) III FEB / 12
Ibuprofen or its salts..

when sold in a modified-release oral dosage form that provides 600 mg or less per dosage unit

III AUG / 16
Ibuprofen or its salts... when sold in an immediate release dosage form containing 400 mg or less per oral dosage unit (in package sizes of up to 18,000 mg) U FEB / 12
Ibutilide or its salts or derivativesPDL I DEC / 13
Icatibant or its saltsPDL

Including but not limited to Icatibant acetate.

I AUG / 14
Icosapent ethylPDL

For veterinary use.

I FEB / 20
Icosapent ethylPDL

For human use: when sold or recommended to reduce the risk of cardiovascular events in statin-treated patients with elevated triglycerides.  

I FEB / 20
Idarubicin or its saltsPDL I DEC / 13
IdarucizumabPDL I AUG / 16
IdebenonePDL I DEC / 13
IdelalisibPDL I MAY / 15
IdoxuridinePDL I DEC / 13
IdursulfasePDL I DEC / 13
IfosfamidePDL I DEC / 13
Imatinib or its saltsPDL I DEC / 13
Imidapril or its saltsPDL I DEC / 13
ImiglucerasePDL I DEC / 13
Imipramine or its saltsPDL I DEC / 13
Imiquimod or its saltsPDL I DEC / 13
Immune globulin products I FEB / 02
Immunogenic substancesPDL

When recommended for sublingual use, including but not limited to: anthoxanthium odoratum L. (sweet vernal grass), betula verrucosa (white birch), dactylis glomerata L. (cocksfoot), lolium perenne L. (rye grass), phleum pratense L. (timothy grass), poa pratense L. (meadow grass).

I JUL / 20
Indacaterol or its salts or derivativesPDL I DEC / 13
Indapamide or its saltsPDL I DEC / 13
Indinavir or its saltsPDL I DEC / 13
IndomethacinPDL I DEC / 13
InfliximabPDL I DEC / 13
Influenza vaccine II DEC / 98
Ingenol mebutate or its derivativesPDL I DEC / 13
Inhaled human insulinPDL I DEC / 13
InosiplexPDL I DEC / 13
Inotersen or its saltsPDL I NOV / 18
Inotuzumab ozogamicinPDL I MAY / 18
Insulin II SEP / 98
InterferonPDL I DEC / 13
Iodinated glycerol II SEP / 98
Iodine and its salts and derivatives except topical preparations or in oral doses of 1 mg or less per day II DEC / 98
Iodochlorhydroxyquin for topical use II SEP / 98
IodochlorohydroxyquinPDL

For veterinary use.

I DEC / 13
IodochlorohydroxyquinPDL

For human use - except in preparations for topical use on the skin.

I DEC / 13
Ipecac and its extracts and derivatives when used as an emetic II OCT / 98
IpilimumabPDL I DEC / 13
Ipratropium or its saltsPDL I DEC / 13
Iproniazid or its saltsPDL I DEC / 13
Irbesartan or its saltsPDL I DEC / 13
Irinotecan or its saltsPDL I DEC / 13
Iron and its salts and derivatives in preparations with more than 30 mg elemental iron per solid dosage unit or 5 mL oral liquid II SEP / 98
Iron derivativesPDL

For human use - including but not limited to ferumoxytol, iron isomaltoside 1000, for parenteral use only.

I DEC / 13
Iron derivativesPDL

For veterinary use - including but not limited to ferumoxytol, for all routes of administration but parenteral.

I DEC / 13
IsatuximabPDL I JUL / 20
Isavuconazole or its saltsPDL I FEB / 19
Isocarboxazid or its saltsPDL I DEC / 13
IsofluranePDL I DEC / 13
IsomethadoneN I JUN / 02
IsoniazidPDL I DEC / 13
Isopropamide and its salts I SEP / 98
Isopropyl myristate in concentration of 50%

for use in the treatment of head lice

III JUL / 07
Isoproterenol (Isoprenaline) or its saltsPDL I DEC / 13
Isosorbide and its salts I SEP / 98
Isotretinoin or its saltsPDL I DEC / 13
Isoxsuprine or its saltsPDL I DEC / 13
Isradipine or its saltsPDL I DEC / 13
Itraconazole or its saltsPDL I DEC / 13
Ivabradine or its salts or derivativesPDL I FEB / 17
Ivacaftor or its derivativesPDL I DEC / 13
Ixazomib or its derivativesPDL I NOV / 16
IxekizumabPDL I AUG / 16

72 résultats


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled